Mark Mcdade - 09 Jun 2022 Form 4 Insider Report for Talaris Therapeutics, Inc. (TRML)

Reporting relationship: Director
Issuer ticker: TRML
Reported as of: 09 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2022, 18:20:54 UTC
Prior SEC filing: 05 Apr 2022
Next SEC filing: 14 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Mary Kay Fenton, attorney-in-fact

Key filing fact

Mark Mcdade filed Form 4 for Talaris Therapeutics, Inc. (TRML) on 13 Jun 2022.

Key facts

This page summarizes Mark Mcdade's Form 4 filing for Talaris Therapeutics, Inc. (TRML).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Jun 2022, 18:20.

Change

Previous filing in this sequence was filed on 05 Apr 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TALS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +14,501
Change %
Price: $0.000000
Shares after: 14,501
Date: 09 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,501
Exercise price: $8.45
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting.